FDAs New Draft Guidance on Computer Software Assurance & HTM

In September 2022, the FDA released a new draft guidance on Computer Software Assurance for Production and Quality System Software, signaling a shift in how healthcare facilities and medical device manufacturers approach software validation. The new guidance emphasizes a risk-based approach to software assurance rather than a blanket validation process. The goal of this new framework is to streamline regulatory compliance while bolstering patient safety. However, what many are concerned about are the far-reaching implications for medical staff and the professionals tasked with managing the changing healthcare technology systems.

Before we deep dive into the guidance, let’s first discuss what is Computer Software Assurance (CSA)? At its core, CSA is a risk-based approach to validate any software that is integral to medical devices, electronic healthcare records, and other critical systems. Unlike the traditional methods that often require intensive documentation and testing for every component, the CSA moves the focus to assess the risk of each software component and how it impacts patient safety and data integrity. It focuses on the following key components:

• Risk Assessment: Identifying and evaluating risks to patients and product quality. Not all software is created equal. High-risk systems require more rigorous testing compared to software that has minimal impact on patient care.
• Modern Testing Methods: The guidance encourages the adoption of modern, automated testing tools. These tools can reduce manual errors, speed up validation processes, and ultimately lead to more reliable systems.
• Targeted Documentation: By reducing unnecessary or irrelevant documentation for low-risk systems, organizations can concentrate their efforts on areas that directly affect patient safety.

So, how does this impact technology managers and medical staff? Although the FDA’s draft guidance represents a significant opportunity for healthcare organizations, it also comes with its own challenges that all teams will need to overcome. On the one hand, a streamlined, risk-based approach can lead to significant improvements in patient safety and operational efficiency. On the other hand, organizations must navigate a complex transition that involves retooling existing processes, enhancing interdepartmental collaboration, and investing in new technologies and training programs. A new review of responsibilities between IT, clinical engineering, and clinical staff will be necessary for a smooth transition to adopting the new processes. Some of the additional responsibilities can be summarized below:

Enhanced Risk Assessments

HTM and any team managing medical technologies will need to implement a comprehensive risk evaluation process. This means we need to go deeper into the analysis of the product. Not just reviewing the functionality, but also on how its failure might affect patient outcomes. A more detailed risk assessment helps prioritize resources for validating high impact systems.

Improving Testing and Validation

To ensure the testing is aligning with the risk-based approach, it will be necessary to adopt and automate testing tools to validate software performance. Technology managers will need to continuously test software and ensure high-risk systems receive rigorous and frequent validations.

Streamlined Compliance Processes

As we discussed about targeting and focusing on the necessary documentation, a tailored validation effort based on risk can reduce maintaining a vast amount of documentation. This allows technology management teams to focus on quality control and rapid responses to any emerging software issues.

Vendor Collaboration

The guidance emphasizes the importance to build strong partnerships with software vendors.  Technology managers need to establish a robust communication channel and partnership agreements to ensure that third-party systems meet the updated risk-based criteria.

Change Management

As software updates and system modifications become subject to dynamic risk assessments, HTM and technology managers need to develop a strong change management process. Adopting proactive monitoring systems will help technology managers rapidly adapt to both regulatory updates and internal system changes.

Interdisciplinary Collaboration

As processes change, it will be important to enhance the collaboration with clinical staff to understand the practical impacts of software on patient care. In addition, providing training and support to clinical teams will help to ensure they recognize potential software issues and understand the new risk-based processes.

Incident Response and Mitigation

As the software is assessed, it is important to develop and refine incident response protocols specifically for software-related issues, ensuring rapid identification, communication, and mitigation of risks.

The FDA’s draft guidance on Computer Software Assurance is transforming how healthcare organizations validate and manage their critical software systems. By emphasizing a risk-based approach, the guidance not only reduces unnecessary documentation, but also ensures that most critical systems receive the attention they deserve. For technology managers, this means revamping risk assessments, compliance processes, and vendor collaborations. For medical staff, it translates to improved system reliability, enhanced training, and a more active role in maintaining safety. As healthcare continues to integrate cutting-edge technology into patient care, it will be important to understand and implement these new guidelines.